What are the specific effects of Ensifentrine?

Ohtuvayre (Ensifentrine)-ensefentine inhalation suspension is an innovative dual phosphodiesterase inhibitor (PDE3 and PDE4), which has both bronchodilator and anti-inflammatory effects. It has become a popular drug in the field of treatment of chronic obstructive pulmonary disease (COPD) in recent years. Its main mechanism is to inhibit PDE3, thereby enhancing intracellular cAMP levels and achieving rapid bronchodilation; at the same time, inhibiting PDE4 helps inhibit the chronic inflammatory process, thereby alleviating the persistent airway inflammatory response in patients with COPD. This dual mechanism makes exefentine different from traditional bronchodilators such as β2 agonists or anticholinergics. It can improve lung function while also regulating inflammation, making it more suitable for long-term use in moderate to severe COPD patients.

Clinically, ensefentin is mainly administered through aerosol inhalation. It has a rapid local onset of action and relatively few systemic side effects. It has a significant alleviation effect especially on patients with frequent nighttime symptoms and obvious shortness of breath in the morning. Potential benefits of this drug in reducing the frequency of exacerbations and improving exercise tolerance and quality of life have also been observed in some trials. However, it needs to be made clear that ensefentin is not a "replacement drug" for the treatment of COPD, but is suitable for patients who have poor control or are intolerant to conventional inhaled drugs as a supplementary option for individualized treatment. In addition, it has also been studied for use in other respiratory diseases such as asthma and cystic fibrosis, showing certain potential for indication expansion.

It is worth noting that exefantine has not yet been approved in mainland China, and there is no experience in its use in China. Therefore, before considering use, it is necessary to conduct a full evaluation and communicate with a doctor whether there are any contraindications or drug interactions. Once it enters the Chinese market in the future, with the accumulation of relevant clinical data, its indications and medication regimens will become clearer, and it is expected to play an increasingly important role in the management of chronic lung diseases.

Reference materials:https://www.drugs.com/monograph/ensifentrine.html